Physician profile
Debra Corrigan
NPI 1043582273
$10,512.70
in general payments reported to CMS, 2019-2025
30 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,334 · 2022: $1,624 · 2023: $2,767 · 2024: $2,610 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,402 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,401.85 |
| Education | $153.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,160.73 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,004.33 | 2021-2025 | Caplyta |
| Lundbeck LLC | $873.12 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $791.71 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $769.48 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $739.49 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $720.96 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $703.55 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $605.31 | 2023-2025 | Auvelity |
| Alkermes, INC. | $577.89 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Ironshore Pharmaceuticals INC. | $562.08 | 2022-2024 | Jornay Pm |
| Corium, LLC | $438.39 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $353.02 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $187.78 | 2021-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $181.82 | 2024-2025 | Cobenfy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $150.06 | 2021-2023 | Perseris |
| Adlon Therapeutics L.P. | $135.26 | 2021 | |
| Idorsia Pharmaceuticals US INC | $96.56 | 2023-2024 | Quviviq |
| Eisai INC. | $81.13 | 2021-2022 | |
| Almatica Pharma LLC | $73.61 | 2021-2023 | Sertraline Hcl, Loreev Xr |
| Merck Sharp & Dohme LLC | $61.63 | 2021-2023 | Belsomra |
| Livanova USA, INC. | $46.39 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Collegium Pharmaceutical, INC. | $45.08 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $39.13 | 2023 | Aplenzin, Wellbutrin |
| Uswm, LLC | $35.00 | 2021 | |
| Brainsway USA INC | $20.93 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.47 | 2024 | Rejoyn |
| Acadia Pharmaceuticals INC | $16.44 | 2021 | |
| Orexo US, INC. | $14.07 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Corrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.